Ondansetron Bluefish

Ondansetron, the active ingredient in Ondansetron Bluefish, is a 5-HT3 receptor antagonist presented as an oral dosage form for oral use. It prevents and treats nausea and vomiting associated with chemotherapy, postoperative recovery, and radiotherapy in patients. GNH USA supplies Ondansetron Bluefish as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Ondansetron acts on the serotonergic pathway to control emesis. - Chemotherapy-induced nausea and vomiting: prevents or reduces nausea and vomiting in patients receiving cytotoxic chemotherapy. - Postoperative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures. - Radiotherapy-induced nausea and vomiting: helps control nausea and vomiting associated with radiation treatment.

Common Side Effects: - Headache: mild to moderate headache may occur. - Constipation: reduced bowel movements are reported. - Dizziness: occasional light‑headedness. - Fatigue: feeling of tiredness. - Diarrhea: loose stools in some patients. - Abdominal pain: mild stomach discomfort.

Serious or Rare Side Effects: - QT prolongation: may lead to cardiac arrhythmia. - Severe allergic reactions: anaphylaxis or angioedema. - Arrhythmias: irregular heart rhythms beyond QT issues. - Serotonin syndrome: rare but potentially life‑threatening when combined with other serotonergic agents. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: abnormal liver enzyme elevations.

Precautions should be observed when prescribing Ondansetron Bluefish. - Assess cardiac history: monitor QT interval in patients with known prolongation or on other QT‑prolonging drugs. - Review electrolyte status: correct hypokalemia, hypomagnesemia before use. - Avoid use in patients with known hypersensitivity to ondansetron or other 5‑HT3 antagonists. - Use caution in hepatic impairment: dose adjustment may be required. - Pregnancy and lactation: evaluate risk‑benefit; limited data are available. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Drug interactions must be considered for safe use. Major Interactions (Avoid): - Concurrent use with other QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics): increased risk of cardiac arrhythmia. - Co‑administration with strong CYP3A4 inhibitors (e.g., aprepitant): may raise ondansetron plasma levels. - Use with other 5‑HT3 antagonists: additive effect, not recommended.

Moderate Interactions (Monitor Closely): - Combination with CYP2D6 substrates (e.g., codeine, tramadol): may alter metabolism of either drug. - Concurrent use with serotonergic agents (e.g., SSRIs, MAO inhibitors): potential for serotonin syndrome. - Use with dexamethasone: may increase the incidence of headache.